Open Access Green as soon as Postprint is submitted to ZB.
Microscopic visualization of metabotropic glutamate receptors on the surface of living cells using bifunctional magnetic resonance imaging probes.
ACS Chem. Neurosci. 5, 128-137 (2014)
A series of bimodal metabotropic glutamate-receptor targeted MRI contrast agents has been developed and evaluated, based on established competitive metabotropic Glu receptor subtype 5 (mGluR5) antagonists. In order to directly visualize mGluR5 binding of these agents on the surface of live astrocytes, variations in the core structure were made. A set of gadolinium conjugates containing either a cyanine dye or a fluorescein moiety was accordingly prepared, to allow visualization by optical microscopy in cellulo. In each case, surface receptor binding was compromised and cell internalization observed. Another approach, examining the location of a terbium analogue via sensitized emission, also exhibited nonspecific cell uptake in neuronal cell line models. Finally, biotin derivatives of two lead compounds were prepared, and the specificity of binding to the mGluR5 cell surface receptors was demonstrated with the aid of their fluorescently labeled avidin conjugates, using both total internal reflection fluorescence (TIRF) and confocal microscopy.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
3.871
0.972
10
16
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Imaging Agents ; Lanthanides ; Mglur5 ; Microscopy ; Mri
Language
english
Publication Year
2014
Prepublished in Year
2013
HGF-reported in Year
2013
e-ISSN
1948-7193
Journal
ACS Chemical Neuroscience
Quellenangaben
Volume: 5,
Issue: 2,
Pages: 128-137
Publisher
American Chemical Society (ACS)
Reviewing status
Peer reviewed
Institute(s)
Institute of Biological and Medical Imaging (IBMI)
POF-Topic(s)
30505 - New Technologies for Biomedical Discoveries
30205 - Bioengineering and Digital Health
30502 - Diabetes: Pathophysiology, Prevention and Therapy
30205 - Bioengineering and Digital Health
30502 - Diabetes: Pathophysiology, Prevention and Therapy
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-552000-001
G-505590-001
G-552000-002
G-505590-001
G-552000-002
PubMed ID
24251400
Scopus ID
84894477652
Erfassungsdatum
2013-12-11